Verification evidence is still being completed.
PDF / print export
Modus Therapeutics
Stockholm, Sweden
- Verified lead
- John Ohd
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Sepsis, Severe Inflammation, Malaria, Anemia of Chronic Inflammation, and Clinical Drug Development
- Review cycle
- May 2026
- Full address
- Modus Therapeutics AB, Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Modus Therapeutics contact page confirming the Stockholm address.
- Editorial note
- Modus Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real clinical-stage inflammatory-disease platform.
Sepsis, Severe Inflammation, Malaria, Anemia of Chronic Inflammation, and Clinical Drug Development
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage therapeutics platform claim
Modus Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real clinical-stage inflammatory-disease platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
Modus Therapeutics
Sepsis, Severe Inflammation, Malaria, Anemia of Chronic Inflammation, and Clinical Drug Development · Clinical-stage therapeutics platform
Modus Therapeutics runs inflammation therapeutics development, clinical program execution, and drug-platform partnering in Stockholm, Sweden.
- Lead
- John Ohd (verified ↗)
- Address
- Modus Therapeutics AB, Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Inflammation Therapeutics Development · Clinical Program Execution · Drug-Platform Partnering
- Founded
- 2017
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
John Ohd
Chief Executive Officer
Full addressModus Therapeutics AB, Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Modus Therapeutics contact page listing the Stockholm office address.
Open sourceClinical-stage therapeutics platform
Stockholm, Sweden. Sepsis, Severe Inflammation, Malaria, Anemia of Chronic Inflammation, and Clinical Drug Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage therapeutics platform claim
Sepsis, Severe Inflammation, Malaria, Anemia of Chronic Inflammation, and Clinical Drug Development
Modus Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real clinical-stage inflammatory-disease platform.
Editorial note
Modus Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real clinical-stage inflammatory-disease platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Inflammation Therapeutics Development
Clinical Program Execution
Drug-Platform Partnering
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Drug-platform R&D systems
Program management infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Modus Therapeutics located?
- Modus Therapeutics operates from Modus Therapeutics AB, Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden, Stockholm, Sweden.
- Who runs Modus Therapeutics?
- Modus Therapeutics is led by John Ohd, Chief Executive Officer. Verified 21 Mar 2026.
- What does Modus Therapeutics do?
- Modus Therapeutics runs inflammation therapeutics development, clinical program execution, and drug-platform partnering in Stockholm, Sweden. Core capabilities: Inflammation Therapeutics Development, Clinical Program Execution, Drug-Platform Partnering.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.